tbuckley/cabot-search huggingface dataset:
Abstract 18239: Yy1 Expression is Sufficient for the Mantenance of Cardiac Progenitor Cell State
Authors: Guang Li, Serge Gregoire, Anthony C. Sturzu, Robert J. Schwartz, Sean M. Wu
Journal: Circulation (2014)

BACKGROUND: Transcription factors and epigenetic modifiers regulate gene expression during cardiac development. We have previously shown that YY1 is essential for the commitment of mesodermal precursors into cardiac progenitor cells (CPCs); however, the role of YY1 in the maintenance of CPC phenotype and their differentiation into cardiomyocytes is unknown. METHODS AND RESULTS: We performed genome-wide expression analysis and targeted real-time qPCR as well as chromatin immunoprecipitation assays for histone modification in mouse embryonic stem cell (ESC)-derived CPCs with and without YY1 over-expression. We found, by genome-wide transcriptional profiling and phenotypic assays, that YY1 overexpression prevents cardiomyogenic differentiation and maintains the proliferative capacity of CPCs. We show further that the ability of YY1 to regulate CPC phenotype is associated with its ability to modulate histone modifications specifically at a developmentally critical enhancer of Nkx2-5 and other key cardiac tran...
Oral therapeutic administration of a probiotic mixture suppresses established Th2 responses and systemic anaphylaxis in a murine model of food allergy
Authors: E. Schiavi, B. Barletta, C. Butteroni, S. Corinti, M. Boirivant, G. Di Felice
Journal: Allergy (2010)

To cite this article: Schiavi E, Barletta B, Butteroni C, Corinti S, Boirivant M, Di Felice G. Oral therapeutic administration of a probiotic mixture suppresses established Th2 responses and systemic anaphylaxis in a murine model of food allergy. Allergy 2011; 66 : 499–508. Abstract Background: No effective treatment is available for food allergy and its primary management still consists of avoiding relevant allergens. Probiotics are claimed to beneficially affect the immune system. We sought to investigate the therapeutic potential of VSL#3 probiotic mixture on specific immune responses and anaphylactic reaction induced in mice by the major food allergen shrimp tropomyosin (ST). Methods: The cytokine production by spleen cell from ST‐sensitized mice upon allergen re‐stimulation in the presence of VSL#3 was analysed. Next, the effects of oral administration of VSL#3 on allergen‐induced anaphylaxis and Th2 response in the murine model of food allergy to ST was investigated by evaluating symptom score and histamine content in the faeces after allergen challenge, antibody response in serum and faeces, and cytokine and transcription factor expression in the jejunum. Results: The in vitro studies on mouse spleen cells indicates that the VSL#3 preparation has the capacity to shift a polarized Th2 response to a Th1/T regulatory‐type profile. Oral therapeutic administration of VSL#3 to ST‐sensitized mice significantly reduces symptom score and histamine release in the faeces following allergen challenge, as well as specific IgE response. In the jejunum, IL‐4, IL‐5 and IL‐13 tissue content was significantly reduced, whereas FOXP3 and IL‐27 mRNA expression, IL‐10, TGF‐β and IFN‐γ tissue content were up‐regulated. Conclusions: Oral therapeutic treatment with the probiotic mixture VSL#3 is effective in redirecting allergen‐specific Th2‐polarized immune responses towards Th1‐T regulatory responses and in the protection against anaphylactic reactions induced by the allergen in a murine model of food allergy.
Abstract 1704: Combination of Pirfenidone and Cisplatin as a potential therapeutic strategy in NSCLC
Authors: Melanie Mediavilla-Varela, David Noyes, Kingsley Boateng, Scott Antonia
Journal: Cancer Research (2014)

Abstract Lung cancer is the leading cause of cancer death in the United States. Due to limited efficacy of current conventional chemotherapy, the majority of patients face poor prognosis and eventually succumb the disease. Therefore, the study of combination therapy using traditional anticancer drugs with novel therapeutic approaches is needed. Pirfenidone is a small molecule that is being used in Phase II and III clinical trials for idiopathic pulmonary fibrosis (IPF). Although it has already been approved for IPF in Europe, there is no known mechanism of action known for the drug. Recently we discovered that Pirfenidone has a detrimental effect on cancer associated fibroblasts (CAFs) as well as in non-small cell lung cancer (NSCLC) cells. Our hypothesis is that Pirfenidone, in combination with standard chemotherapy, will act synergistically and proffer a more potent therapeutic strategy for NSCLC. Our studies show that in a co-culture model there is a decrease in viability on CAFs and NSCLC cells when the combination of Pirfenidone and Cisplatin is used. Furthermore, Pirfenidone and Cisplatin were able to have an anti-tumor effect in a xenograft model of NSCLC and CAFs. In addition, insights in the mechanism by which Pirfenidone and Cisplatin induce synergy in NSCLC cells are being elucidated. Our studies show that the combination of drugs leads to an increase in phosphorylated ERK as well as a decrease in phosphorylated Akt. Thus, involving the PI3K and MAPK/ERK pathways in Pirfenidone/Cisplatin induced cell death. Our lab is the first to recognize the therapeutic potential of combining Pirfenidone and Cisplatin, as well as elucidating the mechanism of action for both drugs in NSCLC. Citation Format: Melanie Mediavilla-Varela, David Noyes, Kingsley Boateng, Scott Antonia. Combination of Pirfenidone and Cisplatin as a potential therapeutic strategy in NSCLC. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1704. doi:10.1158/1538-7445.AM2014-1704
HCV in Egypt
Authors: Rebecca Voelker
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Developing nations work for more access to essential health commodities
Authors: Rohit Sharma
Journal: BMJ (2001)

A group of 16 developing nations, under the umbrella of Partners for Population and Development, have pledged to accelerate “South-South collaboration” (collaboration among developing countries) to stem the tide of lack of access to essential health commodities. The group held a technical consultation at Cochin, south India, last week.

Partners for Population and Development is an inter-government alliance that was formed in 1994 in response to the call at the international conference on population and development in Cairo for intensified South-South collaboration as a key way of achieving the goals set at …
Biomedical Journals Probe Peer Review
Authors: Tracy Hampton
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prevention and Control of Nosocomial Infections.
Authors: Richard P. Wenzel
Journal: Annals of Internal Medicine (1987)

Section 1 Perspectives: the control of infections in hospitals - 1750-1950 cost-effectiveness and cost-benefit analysis in infection control the modern infection control practitioner heath care reform and the hospital epidemiologist in the US. Section 2 Management: regulatory, accreditation, and professional agencies influencing infection control programs controversies in isolation policies and practices organizing for infection control with limited resources microbiology: the role of the clinical laboratory health psychology. Section 3 Epidemiology methods: surveillance, reporting and use of computers what to do about high endemic rates of infection epidemics: identification and management design and analytical issues in studies of infectious diseases statistics in infection control studies. Section 4 Special locations: outpatient/out of hospital care issues infection contra issues in same-day surgery extended care facilities. Section 5 Special problems: the threat of antibiotic resistance optimal use of antibiotics multidrug resistant enterococci and the threat of vancomycin-resistant staphylococcus aurous epidemiology of nosocomial tuberculosis. Section 6 Protecting employees: protecting employees from injury and infection management of exposures to infections. Section 7 Environmental issues: hospital environment for high-risk patients environment issues and nosocomial infections the operating theatre: a special environment area disinfection, sterilization and waste disposal the hospital and pollution: role of the hospital epidemiologist in protecting the environment laboratory-acquired infections infectious biohazards associated with laboratory animal research nosocomial infections related to patient care support. Section 8 Preventing specific infections: handwashing, hand disinfestation, and skin disinfestation nosocomial blood stream infections IV-related infections nosocomial pneumonia urinary tract infections surgical infections including burns perioperative antibiotic prophylaxis infection in implantable prosthetic devices nosocomial gastrointestinal infections uncommon infections of the eye prevention and control of nosocomial infections in obstetrics and gynaecology. Section 9 Special patients: infection in the newborn the paediatric patient the elderly solid-organ transplant patients bone marrow transplant patients the AIDS patient protecting recipients from blood and blood products.
Abstract 1274: Serum Cholesterol Efflux Capacity, a Measure of HDL-C Quality, Varies According to Coronary Artery Disease Status Independently of HDL-C Quantity
Authors: Amit Khera, Amrith Rodrigues, Margarita de la Llera-Moya, George H Rothblat, Daniel J Rader
Journal: Circulation (2009)
A Consortium Approach to Surgical Education in a Developing Country
Authors: Mackenzie Cook, Benjamin M. Howard, Angela Yu, Douglas Grey, Paul B. Hofmann, Alexis M. Moren, Mabula Mchembe, Abbas Essajee, Omari Mndeme, James Peck, William P. Schecter
Journal: JAMA Surgery (2015)

Surgical disease is a global health priority, and improving surgical care requires local capacity building. Single-institution partnerships and surgical missions are logistically limited. The Alliance for Global Clinical Training (hereafter the Alliance) is a consortium of US surgical departments that aims to provide continuous educational support at the Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania (MUHAS). To our knowledge, the Alliance is the first multi-institutional international surgical collaboration to be described in the literature.To assess if the Alliance is effectively responding to the educational needs of MUHAS and Muhimbili National Hospital surgeons.During an initial 13-month program (July 1, 2013, to August 31, 2014), faculty and resident teams from 3 US academic surgical programs rotated at MUHAS as physicians and teachers for 1 month each. To assess the value of the project, we administered anonymous surveys.Anonymous surveys were analyzed on a 5-point Likert-type scale. Free-text answers were analyzed for common themes.During the study period, Alliance members were present at MUHAS for 8 months (1 month each). At the conclusion of the first year of collaboration, 15 MUHAS faculty and 22 MUHAS residents completed the survey. The following 6 areas of educational needs were identified: formal didactics, increased clinical mentorship, longer-term Alliance presence, equitable distribution of teaching time, improved coordination and language skills, and reciprocal exchange rotations at US hospitals. The MUHAS faculty and residents agreed that Alliance members contributed to improved patient care and resident education.A multi-institutional international surgical partnership is possible and leads to perceived improvements in patient care and resident learning. Alliance surgeons must continue to focus on training Tanzanian surgeons. Improving the volunteer surgeons' Swahili-language skills would be an asset. Future efforts should provide more teaching coverage, equitably distribute educational support among all MUHAS surgeons, and collaboratively develop a formal surgical curriculum.
Atlas of Clinical Haematology.
Authors: Herbert Begemann, J. Rastetter, Ludwig Heilmeyer
Journal: Annals of Internal Medicine (1973)

listed in an extensive bibliography containing well over 2000 titles.The last part of the book, con- sisting of some 130 pages, is devoted to working instructions for carrying out various histo- chemical techniques.The book ends with an index.This is a very compact working manual for practical histochemists; it also provides a ready source of reference for the chemical theory on which techniques are based.If an English trans- lation were to be published it would probably become very popular with those whose German is not good enough to allow ready reference to the present text.
Whole Blood Gene Expression Profiling Predicts Therapeutic Response at Six Months in Patients With Polyarticular Juvenile Idiopathic Arthritis
Authors: Kaiyu Jiang, Ashley D. Sawle, M. Barton Frank, Yanmin Chen, Carol A. Wallace, James N. Jarvis
Journal: Arthritis & Rheumatology (2014)

Objective To determine whether gene expression profiles identified in peripheral whole blood samples could be used to determine therapeutic outcome in a cohort of children with newly diagnosed polyarticular juvenile idiopathic arthritis (JIA). Methods Whole blood samples from the Trial of Early Aggressive Therapy (TREAT) in JIA patients were analyzed on Illumina microarrays, and differential gene expression was compared to expression in healthy controls. Microarray results were validated by real‐time quantitative polymerase chain reaction in an independent cohort of samples. Pathway analysis software was used to characterize gene expression profiles. Support vector machines were used to develop predictive models for different patient classes. Results Differential gene expression profiles for rheumatoid factor (RF)–positive and RF‐negative patients were remarkably similar. Pathway analysis revealed a broad range of affected pathways, consistent with current mechanistic theories. Modeling showed that the prognosis at 6 months was strongly linked to gene expression at presentation, irrespective of treatment. Conclusion Gene expression is linked to therapeutic outcome, and gene expression in the peripheral blood may be a suitable target for a prognostic test.
Abstract 12020: Post Infarction Survival and Cardiac Remodeling in a Murine Model of Myocardial Infarction Depends on the Interplay of Interferon Gamma, Neutrophils and Inflammatory Monocytes
Authors: Maike C Knorr, Stefanie Finger, Susanne H Karbach, Sabine Kossmann, Tanja Schönfelder, Thomas Münzel, Philip Wenzel
Journal: Circulation (2014)

Background: Inflammatory myelomonocytic cells are involved in both the initial injury phase and the healing process of myocardial infarction (MI). Objective: To investigate the effects of myelomonocytic cells for cardiac injury and healing in a murine model of MI by scheduled depletion of lysozyme M positive (LysM+) immune cells. Methods and Results: MI was induced in 8 to 12 week old male C57BL/6 mice by ligation of the left anterior descending (LAD) coronary artery. Compared to sham operated LysMCre controls, LysMiDTR transgenic mice that had been depleted of LysM+cells for 3d prior MI by diphtheria toxin injection, revealed a decreased influx of CD45.2+/CD3-/CD11b+/Gr-1high neutrophils into infarcted myocardium 1d post MI. Despite discontinuation of the depletion regimen after LAD ligation, we observed a prolonged reduction of cardiac interferon gamma (INFγ) and tumor necrosis factor alpha mRNA expression as well as worsening of left ventricular ejection fraction (LVEF) until d28 post MI. Continuation ...
Abstract 14864: Risk Markers for Coronary Plaque Progression and Destabilization Beyond LDL-Cholesterol in Patients with Acute Coronary Syndrome
Authors: Takaaki Komatsu, Isao Taguchi, Shiro Nakahara, Sayuki Kobayashi, Yoshihiko Sakai, Michiya Kageyama, Masashi Sakuma, Shigeru Toyoda, Teruo Inoue
Journal: Circulation (2014)

Introduction and Purpose: In acute coronary syndrome (ACS) patients, it is important to stabilize pan-coronary vulnerable plaques as early as possible in ACS patients, in addition to revascularization of the culprit lesion by percutaneous coronary intervention (PCI). Although statins are effective for regression and stabilization of vulnerable plaques in ACS patients, several patients experience plaque progression and/or destabilization despite aggressive control of low-density lipoprotein (LDL)-cholesterol by statins. Therefore, we should do further efforts to research new risk markers beyond LDL-cholesterol and to intervene in them. Methods and Results: In 57 patients with ACS, who underwent emergent percutaneous coronary intervention (PCI), we performed a virtual histology (VH)-IVUS for a non-culprit lesion, at baseline and at the follow-up time (8-10 months), to assess plaque regression/progression and plaque stabilization/destabilization. At the follow-up time, we measured specific biomarkers. All of the patients received aggressive treatment with statins. Change in the total plaque volume by the gray scale IVUS was correlated positively with derivatives of reactive oxygen metabolites (d-ROMs) level (0.32, P&lt;0.05). Change in the volume of destabilized components, i.e., necrotic core plus fibro-fatty compositions, was correlated negatively with the eicosapentaenoic acid to arachidonic acid (EPA/AA) ratio (R=-0.39, P&lt;0.01) and positively with the levels of interleukin (IL)-8 (R=0.31, P&lt;0.01) and d-ROMs (0.32, P&lt;0.01). Multivariate logistic regression analysis showed that only the d-ROMs level was an independent discriminative biomarker for plaque progression (hazard ratio; 1.018, 95% confidence interval; 1.005-1.032, P&lt;0.01) and plaque destabilization (hazard ratio; 1.022, 95% confidence interval; 1.005-1.038, P&lt;0.01). Conclusions: The d-ROMs would be a powerful biomarker to predict plaque progression and destabilization as the residual risk marker beyond LDL-cholesterol. Intervention to oxidative stress state would be the most important residual target beyond LDL cholesterol lowering for plaque regression and stabilization.
Inference engines for phospho-signaling networks, disease mechanism, and clinical outcome at the single cell level
Authors: Garry Nolan
Journal: Clinical Cancer Research (2008)

PL07-01   Intracellular assays of signaling systems has been limited by an inability to correlate functional subsets of cells in complex populations based on active kinase states or other nodal signaling junctions. Such correlations could be important to distinguish changes in signaling status that arise in rare cell subsets during functional activation or in disease manifestation. We have demonstrated the ability to simultaneously detect activated kinases and phosphoproteins in simultaneous pathways in subpopulations of complex cell populations by multi-parameter flow cytometric analysis. We have applied this technology to the study of normal human cell populations as well as several disease states including Acute Myelogenous Leukemia, and Follicular Lymphoma, colon cancer and infiltrating immune cells of cancers among others. The tremendous amounts of correlated data generated via phospho-flow allows amalgamation that automates signaling network determination using Bayesian analysis (and a unique computational approach using a new electronic architecture for a statistics supercomputer). Bringing these together, we have initiated the generation of a comprehensive network topology map of signaling in all primary immune subsets. Thus, we are bringing single cell analysis of multiple kinase pathways together with novel computational and electronic approaches to increase the depth of drug screening to directly reach screening in primary cells.
599. Low-Dose Etoposide Enhances Tumor-Specific Adenovirus-Mediated Cytosine Deaminase Gene Therapy through Induction of Integrin αvβ3 and αvβ5 Overexpression and Upregulation of Human Telomerase Reverse Transcriptase Promoter
Authors: Gia-Shing Shieh, Tzong-Shin Tzai, Yi-Te Yo, Ai-Li Shiau, Chao-Liang Wu
Journal: Molecular Therapy (2004)

Purpose: The human telomerase reverse transcriptase (hTERT) promoter is used to restrict adenoviral expression of suicide or proapoptotic genes in telomerase-positive cancer cells. Etoposide can enhance intratumoral transgene expression in mice immunized with adenoviral vectors. The aim of this study is to evaluate whether greater therapeutic benefit can be achieved by combination treatment of low-dose etoposide and replication-incompetent adenoviral vectors encoding cytosine deaminase (CD) driven by the hTERT promoter for murine bladder carcinoma.